Bexmarilimab plus doxorubicin for advanced soft-tissue sarcoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called bexmarilimab combined with doxorubicin for people with soft-tissue sarcoma that has spread to other parts of the body. The goal is to see if the combination is safe and works better than doxorubicin alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have a type of soft-tissue sarcoma that has spread (metastatic).
- You haven't had doxorubicin or immunotherapy before.
- Your tumor can be measured on scans.
- Your blood counts, liver, and kidney function are within certain limits.
- You agree to use effective birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called HS-20093 combined with other treatments for people with advanced bone or soft tissue sarcoma. It aims to find safe and effective combinations for those who haven't responded to standard treatments.
This trial tests a combination of targeted therapy, chemotherapy, and radiation for advanced soft tissue sarcoma that has not responded to standard treatment. It aims to see if the combination can help patients live longer or shrink their tumors.
This trial tests two injectable medications (OVV-01 and AK112) combined together to treat advanced soft tissue sarcoma—a cancer that has spread or cannot be surgically removed—in patients whose previous treatments have failed. The goal is to see if injecting these drugs directly into tumors can help shrink them and improve outcomes.
This trial tests a new combination of radiation therapy and an immunotherapy approach (called PraG) for people with advanced soft tissue sarcoma that can't be removed by surgery or has spread. The goal is to see if this treatment can shrink tumors and improve outcomes.
This trial tests a first-line treatment for people with advanced or unresectable dedifferentiated liposarcoma that has spread. The goal is to find a therapy that works before other treatments are used.
This trial tests whether adding immunotherapy drugs (anlotinib and penpulimab) to radiation before surgery can help treat soft tissue sarcoma—a type of cancer in muscles, fat, or connective tissue. The goal is to shrink the tumor and improve surgical outcomes.
Hear when a new Soft Tissue Sarcoma (STS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.